



November 13, 2025

BSE Ltd.,
P J Towers,
Dalal Street,
Mumbai - 400 001.
Scrip Code: 524735

National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra-Kurla Complex, Bandra,
Mumbai - 400 051.
Symbol: HIKAL

Dear Sir/Madam,

Subject: Earnings Press Release on the Results of the Company for the quarter and half year ended September 30, 2025

With reference to the subject, we are enclosing a copy of the Press Release on the unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2025.

This is for your information and records.

Thank you,

Yours sincerely,
for HIKAL LIMITED,

Rajasekhar Reddy
Company Secretary & Compliance Officer

Encl: As above

Hikal Ltd.

Admin. Office: Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai - 400 614, India. Tel. + 91-22-6277 0299, + 91-22-6866 0300

Regd. Office: 717, Maker Chambers - 5, Nariman Point, Mumbai - 400 021, India. Tel. +91-22 6277 0477. Fax: + 91-22 6277 0500

www.hikal.com info@hikal.com CIN: L24200MH1988PTC048028



Q2 & H1 FY26 Earnings Release

- Revenue recorded at Rs 319 Crore
- EBITDA stood at Rs. 8 crore
- PAT stood at Rs. (35) Crore
- Hikal's long term credit rating is maintained at A+ by ICRA

Mumbai, November 13, 2025: Hikal Ltd., a preferred long-term partner for leading global life sciences companies, announced its unaudited financial results for the quarter and half year ended 30th September 2025.

Consolidated Performance (in Rs. Crore) :

Rs. In Crs	Q1FY26	Q2FY25	Q2FY26
Revenue	380	453	319
EBITDA	25	75	8
EBITDA%	6.5%	16.5%	2.4%
PAT	(23)	18	(35)
EPS	(1.84)	1.47	(2.82)

Consolidated: Revenue Split

In Rs. Crs	Q1FY26	Q2FY25	Q2FY26
Pharmaceuticals	203	294	190
Crop-Protection	178	159	129

In %	Q1FY26	Q2FY25	Q2FY26
Pharmaceuticals	53%	65%	59%
Crop-Protection	47%	35%	41%



Q2 & H1 FY26: Performance Highlights:

- ⚡ Sales of certain orders executed in Q2 were booked in October 2025. This resulted in under absorption of fixed costs during the quarter
- ⚡ Although operational stability is maintained during the quarter; financials were temporarily affected by pharmaceutical sales deferrals linked to first-half regulatory developments
- ⚡ In the crop protection business, we are focusing on maximizing capacity utilization and enhancing operational efficiency, while proactively developing a robust future pipeline
- ⚡ Our Personal Care business is gaining momentum, aligned with our broader diversification strategy
- ⚡ Balance sheet strengthened, improved debt-equity ratio of 0.55x
- ⚡ Despite the challenges faced in the first half of FY26, we expect a strong recovery in Q3 and Q4, supported by improved demand visibility, higher capacity utilization, and the commercialization of new products.

Q2 & H1 FY26: Pharmaceuticals Performance:

- ⚡ Revenue declined due to a deferment in customer offtake following OAI status and subsequent warning letter
- ⚡ The resumption of supplies is progressing well, and we expect H2 FY26 to bridge majority of the impact of H1 FY26 deferments
- ⚡ Commissioned a state-of-the-art HPAPI lab to boost capabilities in high-potency and complex chemistry development. This will strategically place us in niche segments such as Oncology.
- ⚡ We received positive traction from several global leadership teams from innovator companies during facility visits demonstrating our enhanced capabilities. This has started to result in award of development contracts which will eventually support high margin revenue stream in mid to long term.

Q2 & H1 FY26: Crop-protection Performance:

- ⚡ The Crop Protection industry is undergoing strategic realignments leading to near term challenges as well as long term opportunities
- ⚡ Development of eight projects in CDMO Business are progressing well
- ⚡ Several customer audits and visits completed successfully during the quarter
- ⚡ We are making progress in the Personal Care and Specialty Chemicals space. We expect to commercialize 2-3 products in H2 FY26, in line with our broader diversification strategy



Commenting on the results, Jai Hiremath, Executive Chairman, Hikal Ltd. said,:

Across the global chemical and life sciences industry, persistent headwinds from pricing pressure, overcapacity, and regulatory complexity continue to shape the operating environment. Demand visibility is improving, and capacity utilization is rebounding across geographies. While evolving trade policies and US tariffs add volatility, our diversified base, global footprint, and long-standing partnerships provide resilience.

Consolidated revenue for Q2 stood at ₹ 319 crore, with EBITDA at ₹ 8 crore. For H1 FY26, revenue stood at ₹ 699 crore, with EBITDA at ₹ 32 crore. Lower than expected sales due to deferment during the quarter led to under absorption of fixed costs.

Pharmaceutical business revenue stood at ₹190 crore, with an EBIT margin of -9.2%. Following the US FDA audit in February 2025, we received an OAI and warning letter, leading to H1 FY26 deferment of offtake across our generic and CDMO business, as customers are undertaking their own internal risk assessments before resuming supplies. The resumption of supplies is progressing well, and we expect H2 FY26 to bridge majority of the impact of H1 FY26 deferments.

To address the observations comprehensively, we have launched a robust remediation program, engaged two globally recognized remediation partners, and further strengthened our internal quality organization to ensure full alignment with global regulatory expectations. Our CAPA implementation status has been submitted to the agency in a timely and detailed manner, and we remain actively engaged to expedite a positive resolution.

Our crop protection business reported revenue of ₹ 129 crore, with an EBIT margin of -7.4%. While globally volumes continue to stabilise, the dynamic demand patterns and structural shifts among key innovator customers have led to a muted performance. Our Personal Care business is steadily progressing through its development and launch phase, backed by focused efforts to build a differentiated portfolio of specialty ingredients. This marks a strategic move to diversify beyond our Crop Protection base and enter a fast-growing, high-potential market. With strong momentum in new product development and multiple global RFPs underway, we are building a solid foundation for sustainable growth and long-term value creation.

In the animal health segment, we continue to make steady progress. Validated molecules are now being supplied at pre-commercial volumes which will ramp up further as we receive regulatory approvals across geographies. We have built a strong pipeline of new products which are currently in the development phase. These initiatives position us well for subsequent validations, global regulatory submissions and eventual commercialization through FY27 and beyond.

As part of our innovation and technology strategy, during the quarter we inaugurated a state-of-the-art High Potency API (HPAPI) lab, enhancing our capabilities and entering into a niche segment. We also commissioned a new kilo lab at one of our facilities, further strengthening our early-stage development and scale-up infrastructure.

Despite the challenges faced in the first half of FY26, we expect a strong recovery in Q3 and Q4, supported by improved demand visibility, higher capacity utilization, and the commercialization of new products.



About Hikal Limited

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja, Mahad (Maharashtra) and Panoli (Gujarat). Hikal's R&T facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal is the first Indian life-sciences company to receive the Responsible Care® certification governed by the International Council of Chemical Associations (ICCA).

Safe Harbor Statement

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further information, please contact

Company :

Hikal Limited
CIN: L24200MH1988PTC048028

Mr. Kuldeep Jain
kuldeep_jain@hikal.com

www.hikal.com

Investor Relations Advisors :

Strategic Growth Advisors Pvt. Ltd.
CIN: U74140MH2010PTC204285

Mr. Jigar Kavaia
jigar.kavaia@sgapl.net
+91 9920602034

Ms. Prachi Sharma
prachi.sharma@sgapl.net
+91 8881786789

www.sgapl.net